DRD biotech


Rapid Tests for Assessment of TIA/Ischemic Stroke, Concussions & Risk of Posttraumatic Epilepsy

Results within 5 minutes, with color detection via mobile applications (IOS, Android, W8)

  • On-field or on-site detection (stadium, emergency room, ambulance, combat)
  • User-friendly and affordable cost perstrip test
  • Laboratory devices unnecessary
  • Color detection software adjusts to existing mobile platforms(IOS, Android, W8)
  • Safety of personal data storage in the Cloud, with restricted access

Assays based on identifying glutamate neuroreceptorpeptide fragments and their antibodies in peripheral blood


Currently, there is an urgent need for simple, rapid and on-field/on-site assays assessing TIA, risk of ischemic stroke, severity of concussions & risk of posttraumatic epilepsy

Potential users of assays:

  • Emergency providers
  • Trauma centers
  • Military and civilian hospitals
  • Neurologists, surgeons, and anesthesiologists
  • Sport clubs and schools
  • Medical offices at schools
  • Out-patient services
  • Insurance companies
  • Expert committesthat determine return to work, duty, or play following a brain injury


Investment opportunities

Want know about investment opportunities? Please contact us!

DRD Biotech | DRD ltd.

Zhimbiev Anzhey

+7 (914) 840 09 02


Team [5]

Anzhey Zhimbiev
Anzhey Zhimbiev

CEO, economist and financier with 10-year experience in the...

Evgenia Alexandrova
Evgenia Alexandrova

Medical director, MD, PhD, Сlinical Trials, TBI clinic and...

Investors [1]